# Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

> **NCT06880029** · PHASE1,PHASE2 · RECRUITING · sponsor: **Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.** · enrollment: 20 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **OTHER:** Morning pembrolizumab infusions

## Key facts

- **NCT ID:** NCT06880029
- **Lead sponsor:** Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880029, "Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06880029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*